Key Stats for Vertex Pharmaceuticals Stock
- Pre-Market Price Change for VRTX stock: -4%
- $VRTX Share Price as of Nov. 3: $426
- 52-Week High: $520
- $VRTX Stock Price Target: $481
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Vertex Pharmaceuticals (VRTX) stock slipped in pre-market following the company’s third quarter earnings report, which delivered mixed results despite beating Wall Street’s top and bottom line expectations.
The biotech company reported adjusted earnings of $4.80 per share on revenue of $3.08 billion, surpassing analyst estimates of $4.58 per share and $3.06 billion in sales.
The earnings beat masked some underlying concerns about Vertex’s product portfolio. The company’s cystic fibrosis franchise—which accounts for the vast majority of revenue—delivered combined sales of $2.9 billion from its Trikafta and Alyftrek treatments, beating projections of $2.86 billion.
However, sales of the newer drug Alyftrek came in lighter than expected at just $247 million.
This weak Alyftrek performance suggests Vertex is having trouble converting patients from the older Trikafta treatment to its next-generation therapy.
According to RBC Capital Markets analyst Brian Abrahams, this “affirms recent management commentary that has continued to sound more tempered about the next-gen’s ability to rapidly convert those on Trikafta.”
Beyond cystic fibrosis, Vertex’s newer product launches disappointed as revenue from pain medication Journavx totaled only $20 million versus analyst expectations of $23 million.
Vertex noted there have been 300,000 prescriptions written since launch, but analysts believe heavy reliance on a free drug program may be limiting actual sales.
Even more concerning was Casgevy, Vertex’s gene-editing treatment developed with partner Crispr Therapeutics.
The therapy brought in just $17 million in revenue, dramatically missing the Street’s $43 million forecast.
During the quarter, only 10 patients received infusions of the personalized treatment, down from higher levels in the second quarter and suggesting uptake may be slowing significantly.
On a positive note, Vertex raised the low end of its full-year revenue guidance to a range of $11.9 billion to $12 billion, though this was largely expected given the company’s year-to-date performance.
See analysts’ growth forecasts and price targets for VRTX stock (It’s free!) >>>
What the Market Is Telling Us About VRTX Stock
The market’s negative reaction to Vertex’s earnings reflects growing concerns about the company’s ability to successfully transition its business beyond Trikafta.
The slower-than-expected adoption of both Alyftrek and the company’s newer non-CF products raises questions about Vertex’s growth trajectory.
While the cystic fibrosis franchise remains strong, investors had hoped the company’s expansion into pain management and gene therapy would provide meaningful revenue diversification.
The weak performance of these newer products suggests that path may take longer than anticipated.
Despite these near-term headwinds, VRTX stock has still delivered solid gains this year and remains one of the leading biotechnology companies globally.
Its dominant position in cystic fibrosis provides a stable revenue base, and management continues to invest heavily in expanding its pipeline across multiple disease areas including kidney disease.
Investors should watch whether Vertex can accelerate Alyftrek conversions in coming quarters and whether insurance coverage expansion for Journavx translates into improved sales growth.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does VRTX Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
